These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 20305783)
1. Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma. Balyasnikova IV; Ferguson SD; Sengupta S; Han Y; Lesniak MS PLoS One; 2010 Mar; 5(3):e9750. PubMed ID: 20305783 [TBL] [Abstract][Full Text] [Related]
2. Genetic modification of mesenchymal stem cells to express a single-chain antibody against EGFRvIII on the cell surface. Balyasnikova IV; Franco-Gou R; Mathis JM; Lesniak MS J Tissue Eng Regen Med; 2010 Jun; 4(4):247-58. PubMed ID: 19937911 [TBL] [Abstract][Full Text] [Related]
3. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Nakamizo A; Marini F; Amano T; Khan A; Studeny M; Gumin J; Chen J; Hentschel S; Vecil G; Dembinski J; Andreeff M; Lang FF Cancer Res; 2005 Apr; 65(8):3307-18. PubMed ID: 15833864 [TBL] [Abstract][Full Text] [Related]
4. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Menon LG; Kelly K; Yang HW; Kim SK; Black PM; Carroll RS Stem Cells; 2009 Sep; 27(9):2320-30. PubMed ID: 19544410 [TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of glioblastoma cell invasion by hsa-miR-145-5p and hsa-miR-31-5p co-overexpression in human mesenchymal stem cells. Kurogi R; Nakamizo A; Suzuki SO; Mizoguchi M; Yoshimoto K; Amano T; Amemiya T; Takagishi S; Iihara K J Neurosurg; 2019 Jan; 130(1):44-55. PubMed ID: 29521593 [TBL] [Abstract][Full Text] [Related]
7. Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas. Hata N; Shinojima N; Gumin J; Yong R; Marini F; Andreeff M; Lang FF Neurosurgery; 2010 Jan; 66(1):144-56; discussion 156-7. PubMed ID: 20023545 [TBL] [Abstract][Full Text] [Related]
9. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Morgan RA; Johnson LA; Davis JL; Zheng Z; Woolard KD; Reap EA; Feldman SA; Chinnasamy N; Kuan CT; Song H; Zhang W; Fine HA; Rosenberg SA Hum Gene Ther; 2012 Oct; 23(10):1043-53. PubMed ID: 22780919 [TBL] [Abstract][Full Text] [Related]
10. Human IP10-scFv and DC-induced CTL synergistically inhibit the growth of glioma in a xenograft model. Wang X; Zhang FC; Zhao HY; Lu XL; Sun Y; Xiong ZY; Jiang XB Tumour Biol; 2014 Aug; 35(8):7781-91. PubMed ID: 24816916 [TBL] [Abstract][Full Text] [Related]
11. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Balyasnikova IV; Prasol MS; Ferguson SD; Han Y; Ahmed AU; Gutova M; Tobias AL; Mustafi D; Rincón E; Zhang L; Aboody KS; Lesniak MS Mol Ther; 2014 Jan; 22(1):140-8. PubMed ID: 24002694 [TBL] [Abstract][Full Text] [Related]
12. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo. Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701 [TBL] [Abstract][Full Text] [Related]
13. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231 [TBL] [Abstract][Full Text] [Related]
14. Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Yang B; Wu X; Mao Y; Bao W; Gao L; Zhou P; Xie R; Zhou L; Zhu J Neurosurgery; 2009 Sep; 65(3):610-24; discussion 624. PubMed ID: 19687708 [TBL] [Abstract][Full Text] [Related]
15. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma. Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720 [TBL] [Abstract][Full Text] [Related]